Effect of powder processing on performance of fenofibrate formulations

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 69, Issue 2, 2008, Pages 727-734

  Jain, Rajeev A ^a   Brito, Luis ^a   Straub, Julie A ^a   Tessier, Todd ^a   Bernstein, Howard ^a  

^a Acusphere Inc   (United States)

Author keywords

Fenofibrate; Jet milling; ODTs; Poorly soluble

Indexed keywords

COPOVIDONE S630; CROSPOVIDONE; DOCUSATE SODIUM; FENOFIBRATE; MANNITOL; PEARLITOL 100SD; PLASDONE S630; POVIDONE DERIVATIVE; XYLISORB 700; XYLITOL;

ARTICLE; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; MICROSCOPY; PARTICLE SIZE; POWDER; ROENTGEN SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; TABLET DISINTEGRATION; TABLET FORMULATION; TABLET MANUFACTURE;

ANTILIPEMIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; KINETICS; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS; PROCETOFEN; SOLUBILITY; TABLETS;

EID: 43249093428     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.12.006     Document Type: Article

References (35)

1. Lipinski C. Poor aqueous solubility - an industry wide problem in drug discovery. Am. Pharm. Rev. 5 (2002) 82-85
2. M. Hite, S. Turner, C. Federici, Part 1: Oral delivery of poorly soluble drugs, Pharm. Manuf. and Packing Sourcer, Autumn, 2003, pp. 38-40.
3. Hu J., Johnston K.P., and Williams III R.O. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug. Dev. Indust. Pharm. 30 3 (2004) 233-245
4. Kharb V., Bhatia M., Dureja H., and Kaushik D. Nanoparticle technology for the delivery of poorly water-soluble drugs. Pharm. Tech. 30 2 (2006) 82-92
5. Rasenack N., and Muller B.W. Micron-size drug particles: common and novel micronization techniques. Pharm. Dev. Technol. 9 1 (2004) 1-13
6. Rios M. Bringing formulations to size: strategies for micro- and nanoparticle development. Pharm. Tech. 28 11 (2004) 40-53
7. Jain R., Shah N.H., Malick A.W., and Rhodes C.T. Controlled drug delivery by biodegradable devices: different preparative approaches. Drug Dev. Indust. Pharm. 24 8 (1998) 703-727
8. Jain R.A. The different techniques of manufacturing various biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 21 (2000) 2475-2490
9. Parrott E.L. Milling. In: Lachman L., Lieberman H.A., and Kanig J.L. (Eds). The Theory and Practice of Industrial Pharmacy. third ed. (1987), Verghese Publishing House, India 21-46
10. Cremer K. Orally Disintegrating Dosage Forms (2001), Pharma Concepts GmBH & Co. KG, Germany
11. Pfister W.R., and Ghosh T.K. Orally disintegrating tablets. Pharm. Tech. 29 (2005) 136-150
12. Sant V.P., Smith D., and Leroux J.-C. Novel pH-sensitive supramolecular assemblies for oral delivery of poorly water soluble drugs: preparation and characterization. J. Control. Release 97 2 (2004) 301-312
13. Sant V.P., Smith D., and Leroux J.-C. Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies. J. Control. Release 104 2 (2005) 289-300
14. Sheu M.-T., Yeh C.-M., and Sokoloski T.D. Characterization and dissolution of fenofibrate solid dispersion systems. Int. J. Pharm. 103 2 (1994) 137-146
15. Kerč J., Srčič S., Knez Z., and Senčar-Božič P. Micronization of drugs using supercritical carbon dioxide. Int. J. Pharm. 182 1 (1999) 33-39
16. Munoz A., Guichard J.P., and Reginault P. Micronised fenofibrate. Atherosclerosis 110 Suppl. 1 (1994)
17. T. Ryde, E.E. Gustow, S.B. Ruddy, R. Jain, R. Patel, M.J. Wilkins, Nanoparticulate fibrate formulations, US Patent 7,276,249 (2007).
18. A. Stamm, P. Seth, Fenofibrate pharmaceutical composition having high bioavailability, US Patent 7,041,319 (2006).
19. A. Stamm, P. Seth, Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it, US Patent 7,037,529 (2006).
20. A. Stamm, P. Seth, Fenofibrate pharmaceutical composition having high bioavailability, US Patent 6,652,881 (2003).
21. A.D. Edgar, F.C.O. Bellamy, Combination of fenofibrate and vitamin E, and method of use of same in therapeutic treatments, US Patent 5,880,148 (1999).
22. C. Laruelle, Pharmaceutical dosage formulations of fenofibrate and their applications, US Patent 5,827,536 (1998).
23. L. End, D. Horn, E. Lueddecke, Production of fine particle dye or drug preparations, US Patent 5,700,471 (1997).
24. Saleki-Gerhardt A., Ahlneck C., and Zografi G. Assessment of disorder in crystalline solids. Int. J. Pharm. 101 (1994) 237-247
25. York P., Ticehurst M.D., Osborn J.C., Roberts R.J., and Rowe R.C. Characterization of the surface energetics of milled dl-propanolol hydrochloride using inverse gas chromatography and molecular modeling. Int. J. Pharm. 174 (1998) 179-186
26. Ticehurst M.D., Basford P.A., Dallman C.I., Lukas T.M., Marshall P.V., Nichols G., and Smith D. Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide. Int. J. Pharm. 193 (2000) 247-259
27. Ward G.H., and Shultz R.K. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm. Res. 12 (1995) 773-779
28. Florence S.T., and Salole E.G. Changes in crystallinity and solubility on comminution of digoxin and observations on spironolactone and estradiol. J. Pharm. Pharmacol. 28 (1976) 637-642
29. Elamin A.A., Ahlneck C., Alderborn G., and Nyström C. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. Int. J. Pharm. 111 (1994) 159-170
30. J.-R. Authelin, P. Hosek, Crystalline triamcinolone acetonide produced by a milling process, EU Patent EP1338273 (2003).
31. J.E. Kipp, J.C.T. Wong, M.J. Doty, C.L. Rebbeck, Microprecipitation methods for preparing submicron suspensions, US Patent 7,037,528 (2001).
32. De Villiers M.M. Influence of cohesive properties of micronized drug powders on particle size analysis. J. Pharm. Biomed. Anal. 13 (1995) 191-198
33. De Villiers M.M., and Tiedt L.R. An analysis of fine grinding and aggregation of poorly soluble drug powders in a vibrating ball mill. Pharmazie 51 (1996) 564-567
34. Führer C. Interparticulate attraction mechanisms. In: Alderborn G., and Nyström C. (Eds). Pharmaceutical Powder Compaction Technology (1996), Marcel Deker, Inc., New York, USA 1-15
35. Martin A., Swarbrick J., and Cammarata A. Atomic and molecular structure. Physical Pharmacy. third ed. (1991), Verghese Publishing House, Bombay, India 41-61